Article Figures & Data
Tables
- Table 1.
Clinical characteristic of patients with EGPA. Values are n (%) unless otherwise specified.
Clinical Characteristics Activity, n = 9 Remission, n = 32 Women 8 (88.9) 21 (65.6) Age, yrs, mean ± SD 54.4 ± 5.8 56.0 ± 12.7 Asthma 9 (100) 30 (93.8) Constitutional symptoms 8 (88.9) 28 (87.5) Arthralgia/myalgia 9 (100) 25 (78.1) Skin 6 (66.7) 18 (56.3) Peripheral neuropathy 8 (88.9) 24 (75.0) Pulmonary disease 7 (77.8) 18 (56.3) Heart 3 (33.3) 7 (21.9) Gastrointestinal tract 0 (0) 2 (6.3) Kidney 1 (11.1) 9 (28.1) ENT 7 (77.8) 29 (90.6) MPO-ANCA 5 (55.6) 12 (37.5) BVAS, median (range) 12 (4–21) 0 Glucocorticoids 6 (66.7) 32 (100) Immunosuppressive agents 3 (33.3) 15 (46.9) Azathioprine, n 2 11 Methotrexate, n 1 4 EGPA: eosinophilic granulomatosis with polyangiitis; MPO: myeloperoxidase; ANCA: antineutrophil cytoplasmic antibodies; BVAS: Birmingham Vasculitis Activity Score.
- Table 2.
Serum eotaxin-3 and other biomarker levels. Values are median (range) unless otherwise specified.
Variables Activity, n = 9 Remission, n = 32 Mann-Whitney U Test Univariate Analysis Multivariate Regression Analysis Eotaxin-3, pg/ml 107.6 (54.6–356) 98.2 (58.8–402) 0.68 0.68 — Eotaxin-3, n (%) < 80 pg/ml 12 (37.5) 2 (22.2) — — — 80–200 pg/ml 15 (46.7) 5 (55.6) — — — > 200 pg/ml 5 (15.6) 2 (22.2) — — — IL-6, pg/ml 1.8 (0–59) 0 (0–86) 0.42 0.69 — ESR, mm/h 30 (8–73) 14 (4–52) 0.02 0.01 > 0.2 CRP, mg/l 2.13 (0–5.85) 0 (0–2.71) < 0.01 0.01 0.02 Eosinophil count, × 109/l 1.17 (0.24–2.53) 0.28 (0–0.48) < 0.01 0.02 0.05 IL-6: interleukin 6; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.
In this issue
Eotaxin-3 as a Biomarker of Activity in Established Eosinophilic Granulomatosis with Polyangiitis
